PeptideStack
5.2kquestions
20kanswers
220users

Does hair thinning at week eight of survodutide usually resolve without a dose change?

Asked 23 Sept 2025Modified 10 months agoViewed 6.5k times
24

What I am working with: hair thinning · eight · survodutide.

This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.

What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.

What is the correct sequence, and where is the step that people usually skip?

hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
EM
askedeoin_mcgarry18k3823 Sept 2025
Same situation here, so I will follow this one. – Dr_Priya_Raghunathan 2 months ago
How long since the last dose increase? The timing is most of the diagnosis here. – a_lindgren 23 days ago
add a comment

2 Answers

Accepted answer first, then by votes
97

Accepted answer

Week 8 is day 56: on a four-week ladder that is week 4 of dose step 2, and — at the seven-day half-life this class runs on — 8 half-lives in. Steady state is about five half-lives, so day 35 is where the concentration stops climbing on its own. Day 56 is 3 weeks past it, which means the level is no longer the variable. That distinction is most of the question: at week 4 of a step, an effect that is still accumulating is indistinguishable from one that is not resolving unless you know which side of day 35 you are on. Telogen effluvium lags its trigger by roughly three months, which is twelve weeks. Week 8 therefore points at about week 0 as the trigger — which is before the first dose, so the deficit and the agent are not the only candidates and probably not the first ones. Dose decisions are made under supervision, and nothing here is medical advice.

Patterned rather than diffuse loss is a different condition and points elsewhere.

Worth checking: ferritin, thyroid function and vitamin D. Low ferritin in particular is associated with shedding at levels that are not low enough to cause anaemia.

Gastrointestinal adverse events, indicative pooled rates

EventActive armPlacebo armTiming
Nausea40–45 %15–20 %Peaks 1–2 wk after each step
Vomiting15–25 %5–8 %Follows nausea
Diarrhoea20–30 %10–15 %Early, variable
Constipation20–25 %8–12 %Later onset, persistent
Discontinuation for GI events4–7 %1–2 %Mostly during escalation

Ranges span agents and doses; read the specific prescribing information for a specific figure.

In telogen effluvium a stressor shifts a large fraction of follicles from anagen into telogen simultaneously. Because telogen lasts around two to three months, the shed appears two to four months after the trigger rather than during it.

The two-to-four-month latency follows directly from the duration of the telogen phase and is the diagnostic feature of the condition.

Nothing here is medical advice.

Protein intake is the modifiable nutritional factor worth attending to.

edited 25 Sept 2025 by pieter_maas — added the citation requested in comments

shareimprove this answerflag
PM
answered · acceptedpieter_maas14k1724 Sept 2025
6The distinction between escalation-related and steady-state is the useful part. – bufferline42 8 months ago
5Worth adding that the area postrema explanation also predicts why it settles. – rosa_mendieta 7 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
37

Answering this needs the rate of weight loss and the protein intake, since those are the two modifiable contributors.

Nothing topical has strong evidence for accelerating recovery from telogen effluvium specifically, as distinct from androgenetic loss where the evidence is entirely different.

Recovery follows the same timeline in reverse: shedding stops within a few months of the trigger resolving, and visible density returns over six to twelve months as regrowth reaches length.

Research-use compounds are not approved for human use.

It resolves in most cases over six to twelve months. That is genuinely the answer.

shareimprove this answerflag
EM
answeredeoin_mcgarry18k386 Oct 2025
6This should be linked from the help pages. – eighty_six_hours 10 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.